Context-dependent effects of IL-2 rewire immunity into distinct cellular circuits

Interleukin 2 (IL-2) is a key homeostatic cytokine, with potential therapeutic applications in both immunogenic and tolerogenic immune modulation. Clinical application has been hampered by pleiotropic functionality and wide-spread receptor expression, with unexpected adverse events during trials. To characterize the IL-2 homeostatic network, we developed a novel mouse strain allowing IL-2 production to be diverted. Rewiring of IL-2 production to diverse leukocyte sources allowed the identification of contextual influences over IL-2 impact. Network analysis identified a priority access for Tregs, and a competitive fitness cost induced among both Tregs and conventional CD4 T cells for IL-2 production. CD8 T cells and NK cells, by contrast, exhibited a preference for autocrine IL-2 production. IL-2 sourced from dendritic cells amplified the Treg circuit, while IL-2 produced by B cells induced two context-dependent circuits: dramatic expansion of CD8+ Tregs and ILC2 cells. The former was associated with an unexpected concentration of rare CD8+ Tregs in B cell zones, while the latter drove a downstream, IL-5-mediated, eosinophilic circuit. The source-specific effects demonstrate the contextual influence of IL-2 function and potentially explain unexpected adverse effects observed during clinical trials of exogenous IL-2. Targeted IL-2 production therefore has the potential to amplify or quench particular circuits in the IL-2 network, based on clinical desirability. Graphical abstract

[1]  Anne E Carpenter,et al.  CellProfiler 4: improvements in speed, utility and usability , 2021, BMC Bioinformatics.

[2]  Richard L. Halpert,et al.  AutoSpill is a principled framework that simplifies the analysis of multichromatic flow cytometry data , 2021, Nature Communications.

[3]  V. Niederlova,et al.  CD8+ Tregs revisited: A heterogeneous population with different phenotypes and properties , 2021, European journal of immunology.

[4]  Yong Liu,et al.  TGF-β and Eomes control the homeostasis of CD8+ regulatory T cells , 2020, The Journal of experimental medicine.

[5]  M. Gavin,et al.  An IL-2 mutein engineered to promote expansion of regulatory T cells arrests ongoing autoimmunity in mice , 2020, Science Immunology.

[6]  Carly E. Whyte,et al.  Microglia Require CD4 T Cells to Complete the Fetal-to-Adult Transition , 2020, Cell.

[7]  S. Gupta,et al.  A role for cell‐autocrine interleukin‐2 in regulatory T‐cell homeostasis , 2020, Immunology.

[8]  Marius Pachitariu,et al.  Cellpose: a generalist algorithm for cellular segmentation , 2020, Nature Methods.

[9]  L. Williams,et al.  Serum cytokines elevated during gluten‐mediated cytokine release in coeliac disease , 2020, Clinical and experimental immunology.

[10]  G. Kroemer,et al.  Effects of interleukin-2 in immunostimulation and immunosuppression , 2019, The Journal of experimental medicine.

[11]  T. Waldmann,et al.  IL-2 receptors preassemble and signal in the ER/Golgi causing resistance to antiproliferative anti–IL-2Rα therapies , 2019, Proceedings of the National Academy of Sciences.

[12]  Zhichen Sun,et al.  A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control , 2019, Nature Communications.

[13]  E. Azizi,et al.  IL-2 production by self-reactive CD4 thymocytes scales regulatory T cell generation in the thymus , 2019, The Journal of experimental medicine.

[14]  J. Casanova,et al.  IFN-γ and CD25 drive distinct pathologic features during hemophagocytic lymphohistiocytosis. , 2019, The Journal of allergy and clinical immunology.

[15]  J. Kelsen,et al.  Innate lymphoid cells support regulatory T cells in the intestine through interleukin-2 , 2019, Nature.

[16]  L. Nguyen,et al.  Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2 , 2019, Cancer Immunology and Immunotherapy.

[17]  Brian D. Weitzner,et al.  De novo design of potent and selective mimics of IL-2 and IL-15 , 2019, Nature.

[18]  J. Todd,et al.  A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease , 2018, Journal of autoimmunity.

[19]  Peter Vogel,et al.  Hippo Kinases Mst1 and Mst2 Sense and Amplify IL‐2R‐STAT5 Signaling in Regulatory T Cells to Establish Stable Regulatory Activity , 2018, Immunity.

[20]  Jamie B. Spangler,et al.  Engineering a Single-Agent Cytokine/Antibody Fusion That Selectively Expands Regulatory T Cells for Autoimmune Disease Therapy , 2018, The Journal of Immunology.

[21]  W. Leonard,et al.  Biology and regulation of IL-2: from molecular mechanisms to human therapy , 2018, Nature Reviews Immunology.

[22]  J. Vela-Ojeda,et al.  Description of CD8+ Regulatory T Lymphocytes and Their Specific Intervention in Graft-versus-Host and Infectious Diseases, Autoimmunity, and Cancer , 2018, Journal of immunology research.

[23]  J. Bluestone,et al.  Revisiting IL-2: Biology and therapeutic prospects , 2018, Science Immunology.

[24]  D. Bending,et al.  A timer for analyzing temporally dynamic changes in transcription during differentiation in vivo , 2018, The Journal of cell biology.

[25]  M. Farrar,et al.  Identification of Cellular Sources of IL-2 Needed for Regulatory T Cell Development and Homeostasis , 2018, The Journal of Immunology.

[26]  D. Cantrell,et al.  Interleukin-2 shapes the cytotoxic T cell proteome and immune environment–sensing programs , 2018, Science Signaling.

[27]  David Baker,et al.  Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes , 2018, Science.

[28]  D. Bending,et al.  A temporally dynamic Foxp3 autoregulatory transcriptional circuit controls the effector Treg programme , 2018, bioRxiv.

[29]  M. Stone.  Regulation of Chemokine–Receptor Interactions and Functions , 2017, International journal of molecular sciences.

[30]  Morgan Huse,et al.  A Tunable Diffusion‐Consumption Mechanism of Cytokine Propagation Enables Plasticity in Cell‐to‐Cell Communication in the Immune System , 2017, Immunity.

[31]  M. Stone,et al.  Mechanisms of Regulation of the Chemokine-Receptor Network , 2017, International journal of molecular sciences.

[32]  P. Hawkins,et al.  Phosphoproteomic Analyses of Interleukin 2 Signaling Reveal Integrated JAK Kinase-Dependent and -Independent Networks in CD8+ T Cells , 2016, Immunity.

[33]  H. Kita,et al.  Group 2 Innate Lymphoid Cells Promote an Early Antibody Response to a Respiratory Antigen in Mice , 2016, The Journal of Immunology.

[34]  A. Rudensky,et al.  An essential role for IL-2 receptor in regulatory T cell function , 2016, Nature Immunology.

[35]  C. Wouters,et al.  IL-2 consumption by highly activated CD8 T cells induces regulatory T-cell dysfunction in patients with hemophagocytic lymphohistiocytosis. , 2016, The Journal of allergy and clinical immunology.

[36]  I. Maclennan,et al.  Follicular Helper T Cells. , 2016, Annual review of immunology.

[37]  A. McKenzie,et al.  IL-4-producing ILC2s are required for the differentiation of TH2 cells following Heligmosomoides polygyrus infection , 2016, Mucosal Immunology.

[38]  Ronald N. Germain,et al.  Immune homeostasis enforced by co-localized effector and regulatory T cells , 2015, Nature.

[39]  Jamie B. Spangler,et al.  Interleukin-2 activity can be fine tuned with engineered receptor signaling clamps. , 2015, Immunity.

[40]  D. Klatzmann,et al.  Human and Mouse CD8+CD25+FOXP3+ Regulatory T Cells at Steady State and during Interleukin-2 Therapy , 2015, Front. Immunol..

[41]  Jamie B. Spangler,et al.  Insights into cytokine-receptor interactions from cytokine engineering. , 2015, Annual review of immunology.

[42]  D. Klatzmann,et al.  Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients. , 2015, Journal of autoimmunity.

[43]  Ruslan Medzhitov,et al.  Homeostasis, Inflammation, and Disease Susceptibility , 2015, Cell.

[44]  R. Maizels,et al.  CCR7-dependent trafficking of RORγ+ ILCs creates a unique microenvironment within mucosal draining lymph nodes , 2015, Nature Communications.

[45]  R. Locksley,et al.  Interleukin-5-producing group 2 innate lymphoid cells control eosinophilia induced by interleukin-2 therapy. , 2014, Blood.

[46]  R. Geffers,et al.  Fluorochrome‐based definition of naturally occurring Foxp3+ regulatory T cells of intra‐ and extrathymic origin , 2014, European journal of immunology.

[47]  M. Atkins,et al.  High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014 , 2014, Journal of Immunotherapy for Cancer.

[48]  A. Rudensky,et al.  Control of the Inheritance of Regulatory T Cell Identity by a cis Element in the Foxp3 Locus , 2014, Cell.

[49]  S. Rosenberg.  IL-2: The First Effective Immunotherapy for Human Cancer , 2014, The Journal of Immunology.

[50]  Taeko Dohi,et al.  The epigenetic regulator Uhrf1 facilitates the proliferation and maturation of colonic regulatory T cells , 2014, Nature Immunology.

[51]  Adrian Liston,et al.  Homeostatic control of regulatory T cell diversity , 2014, Nature Reviews Immunology.

[52]  D. Klatzmann,et al.  Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial. , 2013, The lancet. Diabetes & endocrinology.

[53]  A. Liston,et al.  IL-2 coordinates IL-2–producing and regulatory T cell interplay , 2013, The Journal of experimental medicine.

[54]  Susan M. Schlenner,et al.  Antiapoptotic Mcl-1 is critical for the survival and niche-filling capacity of Foxp3+ regulatory T cells , 2013, Nature Immunology.

[55]  S. Zelenay,et al.  Genetic Tracing via DNGR-1 Expression History Defines Dendritic Cells as a Hematopoietic Lineage , 2013, Cell.

[56]  Ana R. Pacios,et al.  Human IL-2 Mutein with Higher Antitumor Efficacy Than Wild Type IL-2 , 2013, The Journal of Immunology.

[57]  J. Ritz,et al.  Low-Dose Interleukin-2 Therapy Restores Regulatory T Cell Homeostasis in Patients with Chronic Graft-Versus-Host Disease , 2013, Science Translational Medicine.

[58]  N. Tsuji,et al.  Ontogeny and localization of the cells produce IL-2 in healthy animals. , 2013, Cytokine.

[59]  Ana R. Pacios,et al.  Efficacy Than Wild Type IL-2 Human IL-2 Mutein with Higher Antitumor , 2013 .

[60]  L. Fetler,et al.  Regulatory T Cells Increase the Avidity of Primary CD8+ T Cell Responses and Promote Memory , 2012, Science.

[61]  V. Pande,et al.  Mechanistic and structural insight into the functional dichotomy between interleukin-2 and interleukin-15 , 2012, Nature Immunology.

[62]  Alexandra C. Chadwick,et al.  CD8+ Foxp3+ Regulatory T Cells Are Induced during Graft-versus-Host Disease and Mitigate Disease Severity , 2012, The Journal of Immunology.

[63]  Johannes E. Schindelin,et al.  Fiji: an open-source platform for biological-image analysis , 2012, Nature Methods.

[64]  G. Hill,et al.  Identification and expansion of highly suppressive CD8(+)FoxP3(+) regulatory T cells after experimental allogeneic bone marrow transplantation. , 2012, Blood.

[65]  Kendall A. Smith,et al.  Conditional IL-2 Gene Deletion: Consequences for T Cell Proliferation , 2012, Front. Immun..

[66]  Vijay S. Pande,et al.  Exploiting a natural conformational switch to engineer an Interleukin-2 superkine , 2012, Nature.

[67]  J. Ritz,et al.  Interleukin-2 and regulatory T cells in graft-versus-host disease. , 2011, The New England journal of medicine.

[68]  Y. Kerdiles,et al.  Fate mapping analysis of lymphoid cells expressing the NKp46 cell surface receptor , 2011, Proceedings of the National Academy of Sciences.

[69]  K. Lahl,et al.  CD8+Foxp3+ T cells share developmental and phenotypic features with classical CD4+Foxp3+ regulatory T cells but lack potent suppressive activity , 2011, European journal of immunology.

[70]  Michael W. Sneddon,et al.  Single-cell quantification of IL-2 response by effector and regulatory T cells reveals critical plasticity in immune response , 2010, Molecular systems biology.

[71]  J. Dutcher,et al.  Novel Management of Pruritus in Patients Treated With IL-2 for Metastatic Renal Cell Carcinoma and Malignant Melanoma , 2010, Journal of immunotherapy.

[72]  Xiaolei Tang,et al.  Inhibition of follicular T helper cells by CD8+ Treg is essential for self tolerance , 2010, Nature.

[73]  J. Sprent,et al.  IL-2/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor α subunit CD25 , 2010, Proceedings of the National Academy of Sciences.

[74]  P. Nigam,et al.  Expansion of FOXP3+ CD8 T Cells with Suppressive Potential in Colorectal Mucosa Following a Pathogenic Simian Immunodeficiency Virus Infection Correlates with Diminished Antiviral T Cell Response and Viral Control , 2010, The Journal of Immunology.

[75]  Kim L Kusser,et al.  Cytokine-producing effector B cells regulate type 2 immunity to H. polygyrus. , 2009, Immunity.

[76]  A. Rudensky,et al.  Differentiation of regulatory Foxp3+ T cells in the thymic cortex , 2008, Proceedings of the National Academy of Sciences.

[77]  Kendall A. Smith,et al.  The quantal theory of immunity and the interleukin‐2‐dependent negative feedback regulation of the immune response , 2008, Immunological reviews.

[78]  M. Busslinger,et al.  Instructive role of the transcription factor E2A in early B lymphopoiesis and germinal center B cell development. , 2008, Immunity.

[79]  E. Chi,et al.  Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. , 2008, Immunity.

[80]  J. Schlom,et al.  IL-2/Anti-IL-2 Antibody Complex Enhances Vaccine-Mediated Antigen-Specific CD8+ T Cell Responses and Increases the Ratio of Effector/Memory CD8+ T Cells to Regulatory T Cells1 , 2008, The Journal of Immunology.

[81]  T. Malek,et al.  The biology of interleukin-2. , 2008, Annual review of immunology.

[82]  Kendall A. Smith,et al.  Negative Feedback Regulation of T Cells via Interleukin-2 and FOXP3 Reciprocity , 2008, PloS one.

[83]  S. Ishihara,et al.  CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation–mediated apoptosis of effector CD4+ T cells , 2007, Nature Immunology.

[84]  S. Ju,et al.  Cutting Edge: A Regulatory T Cell-Dependent Novel Function of CD25 (IL-2Rα) Controlling Memory CD8+ T Cell Homeostasis1 , 2007, The Journal of Immunology.

[85]  Linda V. Sinclair,et al.  Differential regulation of T-cell growth by IL-2 and IL-15. , 2006, Blood.

[86]  A. Tyznik,et al.  Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells , 2006, Nature.

[87]  J. Sprent,et al.  Selective Stimulation of T Cell Subsets with Antibody-Cytokine Immune Complexes , 2006, Science.

[88]  A. Rudensky,et al.  A function for interleukin 2 in Foxp3-expressing regulatory T cells , 2005, Nature Immunology.

[89]  E. Hatzimichael,et al.  Serum interleukin (IL)‐1, IL‐2, sIL‐2Ra, IL‐6 and thrombopoietin levels in patients with chronic myeloproliferative diseases , 2005, British journal of haematology.

[90]  D. Lauffenburger,et al.  High-affinity CD25-binding IL-2 mutants potently stimulate persistent T cell growth. , 2005, Biochemistry.

[91]  E. Bissonette,et al.  Low-dose IL-2 induces cytokine cascade, eosinophilia, and a transient Th2 shift in melanoma patients , 2005, Cancer Immunology, Immunotherapy.

[92]  H. Ljunggren,et al.  Targeting IL-2 to the endoplasmic reticulum confines autocrine growth stimulation to NK-92 cells. , 2005, Experimental hematology.

[93]  E. Bissonette,et al.  Assessment of the Toxicities of Systemic Low-Dose Interleukin-2 Administered in Conjunction with a Melanoma Peptide Vaccine , 2004, Journal of immunotherapy.

[94]  F. Marincola,et al.  Forecasting the cytokine storm following systemic interleukin (IL)-2 administration , 2004, Journal of Translational Medicine.

[95]  H. Bozkurt,et al.  Change in Serum Concentrations of Interleukin-2 and Interferon-γ during Treatment of Tuberculosis , 2004, The Journal of international medical research.

[96]  T. Nutman,et al.  The role of eosinophils in host defense against helminth parasites. , 2004, The Journal of allergy and clinical immunology.

[97]  M. Dietrich,et al.  Preliminary clinical observations with recombinant interleukin-2 in patients with AIDS or LAS , 2004, Blut.

[98]  D. Lauffenburger,et al.  Interleukin‐2 mutants with enhanced α‐receptor subunit binding affinity , 2003 .

[99]  L. Schoonjans,et al.  Improved Generation of Germline‐Competent Embryonic Stem Cell Lines from Inbred Mouse Strains , 2003, Stem cells.

[100]  W. Leonard,et al.  IL-2 negatively regulates IL-7 receptor α chain expression in activated T lymphocytes , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[101]  Ş. Çavuşlu,et al.  Serum Interleukin 2 Levels in Patients with Rheumatoid Arthritis and Correlation with Insulin Sensitivity , 2002, The Journal of international medical research.

[102]  W. Leonard,et al.  IL-2 negatively regulates IL-7 receptor alpha chain expression in activated T lymphocytes. , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[103]  M. Milowsky,et al.  Advanced renal cell carcinoma , 2020, Current treatment options in oncology.

[104]  M. Dewhirst,et al.  Effective tumor therapy with plasmid-encoded cytokines combined with in vivo electroporation. , 2001, Cancer research.

[105]  E. Rothenberg,et al.  A New Regulatory Region of the IL-2 Locus That Confers Position-Independent Transgene Expression1 , 2001, The Journal of Immunology.

[106]  M. Moroni,et al.  Eosinophils and C4 predict clinical failure of combination immunotherapy with very low dose subcutaneous interleukin-2 and interferon in renal cell carcinoma patients. , 2000, Haematologica.

[107]  J. Sosman,et al.  Daily subcutaneous ultra-low-dose interleukin 2 with daily low-dose interferon-alpha in patients with advanced renal cell carcinoma. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[108]  V. Prasad,et al.  T Cells On , 1998, Science.

[109]  P. Cremaschi,et al.  Effects of interleukin-2 for the treatment of malignant mesothelioma. , 1998, Oncology Report.

[110]  J. García,et al.  High-dose systemic interleukin-2 therapy in stage IV neuroblastoma for one year after autologous bone marrow transplantation: pilot study. , 1996, Medical and pediatric oncology.

[111]  A. Ardizzoni,et al.  Biologic and clinical effects of continuous infusion interleukin‐2 in patients with non‐small cell lung cancer , 1994, Cancer.

[112]  K. Kim.  CD4+T Cells , 1993 .

[113]  L. Neckers,et al.  A Phase I Study of Interleukin‐2 in Children with Cancer , 1992, The American journal of pediatric hematology/oncology.

[114]  Philippe Soriano,et al.  Promoter traps in embryonic stem cells: a genetic screen to identify and mutate developmental genes in mice. , 1991, Genes & development.

[115]  P. Weller,et al.  Human eosinophils express functional interleukin 2 receptors. , 1991, The Journal of clinical investigation.

[116]  W. Paul,et al.  Interleukin 4 is important in protective immunity to a gastrointestinal nematode infection in mice. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[117]  F. Tarentini Trojani.  [Recombinant interleukin-2]. , 1991, La Clinica terapeutica.

[118]  H. Enokihara,et al.  Interleultin‐2 treatment‐associated eosinophilia is mediated by interleultin‐5 production , 1990 .

[119]  A. Barrett,et al.  Recombinant interleukin 2 for acute myeloid leukaemia in first complete remission: a pilot study. , 1990, Leukemia research.

[120]  K. Saito,et al.  T cells from eosinophilic patients produce interleukin-5 with interleukin-2 stimulation. , 1989, Blood.

[121]  H. Enokihara,et al.  Interleukin 2 stimulates the T‐cells from patients with eosinophilia to produce CFU‐Eo growth stimulating factor , 1988, British journal of haematology.

[122]  H. Peter,et al.  In vivo effects of interleukin 2 on lymphocyte subpopulations in a patient with a combined immunodeficiency. , 1984, Immunobiology.

[123]  Kendall A. Smith,et al.  T cell growth factor: parameters of production and a quantitative microassay for activity. , 1978, Journal of immunology.